Movement Alert|10x Genomics, Inc. Falls 4.02% in Regular Trading, Collaboration Update Fails to Offset Target Price Cuts and Executive Selling Pressure

Market Focus11-18 00:00

On November 17, 10x Genomics, Inc. fell 4.02% in Regular Trading, trading around $53.535 per share, with turnover of $30.6552 million.

The move followed a market focus on post-earnings valuation pressure, as several firms lowered price targets and recent CEO share sales continued to weigh on sentiment, even after the company disclosed two autoimmune biomarker research collaborations.

Earlier this month, 10x Genomics, Inc. reported third-quarter EPS of negative $0.15, better than expectations for a loss of about $0.25 to $0.27, while revenue of $150.667 million exceeded estimates near $148 million. The company also raised full-year revenue guidance to $625 million-$635 million, above the roughly $620.8 million consensus. Even so, target prices were cut after the report, including UBS to $61 from $90, adding to pressure on the stock’s valuation framework.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment